Over the last few years, it has been suggested that Knee Ostheoarthritis (KOA) incidence and progression could potentially be related to skeletal muscle characteristics. In particular, weakness of the quadriceps muscle would be a key determinant of KOA. However the mechanisms underpinning the influence of skeletal muscle in the pathophysiology of ostheoarthritis (OA) are poorly understood.
Crosstalk between skeletal muscle and structures around and in the joint is of interest. In physical deconditioning and aging, it has been reported that skeletal muscle can be replaced by adipose tissue. Several factors involved in the development of OA but also of adipose tissue may be involved in these muscular changes. Of interest, in patients with KOA, quadriceps weakness is an ubiquitous clinical finding. Infiltration of adipose tissue in skeletal muscle has been shown to affect muscle strength and mobility and be linked to cartilage volume loss and the occurrence/progression of KOA.
The main objective of this study is to compare the characteristics of the Hoffa tissus and the intamuscular fat (IMF) tissus in the quadriceps muscle in patients with gonarthrosis requiring total knee prosthesis.
This is a single-centre study based on a collection of surgical waste and is categorized as Research Not Involving Human subjects.
Adult patient, aged between 40 and 85 years
Patient having a confirmed diagnosis of knee ostheoarthritis
Patient undergoing a surgery for a total knee prosthesis for knee ostheoarthritis
None
Patients aged between 40 and 85 years that have a scheduled surgery for a total knee prosthesis and have a confirmed diagnosis of knee ostheoarthritis.
Case-only
Prospective
BIOPSY
Other interventionbiopsy
Comparison between Hoffa tissue and intramuscular fat tissue (quadriceps): adipose tissue size differences
size mesured in mm
Comparison between Hoffa tissue and intramuscular fat tissue (quadriceps): lipid levels
level mesured in %
Comparison between Hoffa tissue and intramuscular fat tissue (quadriceps):fibrotic tissue
rate mesured in %
Click on the lead sponsor to view all of their trials.
